Stereotaxis, Inc.

Stereotaxis, Inc. announced an agreement to acquire Robocath, a French innovator in advanced mechanical robotic technology for interventional cardiology and neurointerventions, on April 14, 2026. For the first quarter ended March 31, 2026, the company reported a decrease in total revenue to $6.29 million from $7.47 million in the prior year period. Net loss attributable to common stockholders increased slightly to $6.17 million, or $0.06 per share, compared to $6.14 million, or $0.07 per share, in Q1 2025. The company also secured $4.72 million in financing activities, primarily from an at-the-market equity offering.

Stereotaxis reported Q1 2026 revenue of $6.3 million, a decrease from $7.5 million in the prior year, resulting in a net loss of ($5.9) million. Despite the financial decline, the company achieved significant milestones including US FDA approvals for its MAGiC catheter and Synchrony digital operating room system, which are now being commercialized. Additionally, Stereotaxis announced a definitive agreement to acquire Robocath, aiming to create a leading robotic platform. The company projects double-digit revenue growth for the full year 2026, expecting to surpass $40 million.

Stereotaxis reported Q1 2026 financial results and significant business updates, including a definitive agreement to acquire Robocath to create a leading robotic platform. The company also announced U.S. FDA approvals for its proprietary MAGiC catheter and Synchrony digital operating room system, which are now being utilized. While Q1 revenue decreased to $6.3 million from $7.5 million year-over-year and net loss slightly widened to $(5.9) million, Stereotaxis anticipates double-digit revenue growth for the full year 2026, expecting to surpass $40 million, driven by new product adoption and manufacturing ramp-up.

Stereotaxis announced the successful treatment of the first US patient using its MAGiC™ robotically-navigated magnetic interventional cardiac ablation catheter. The MAGiC catheter, recently FDA PMA approved, is specifically designed for arrhythmia in patients with complex congenital heart disease. The initial procedure at Oregon Health & Science University successfully treated a patient with challenging anatomy, who had previously failed manual ablation attempts, with no recurrence weeks post-procedure. This marks a significant advancement in treating complex arrhythmia patients.

Stereotaxis, Inc. announced it will release its first quarter 2026 financial results on Tuesday, May 12, 2026, after the close of U.S. financial markets. The company will host a conference call and webcast at 4:30 p.m. EST on the same day to discuss the results and corporate developments. Investors can access the live call via dial-in or the webcast through the company's investor relations website.

Stereotaxis, Inc. has entered into a Share Sale Agreement to acquire 100% of Robocath, a French innovator in advanced mechanical robotic technology for interventional cardiology and neurointerventions. The initial consideration for the acquisition is $20.0 million, payable in cash, Stereotaxis common stock (valued at $2.00 per share), or a combination. Additionally, Robocath shareholders could receive up to $25 million in earnout payments if certain performance targets are met. The acquisition is subject to various closing conditions and is expected to finalize in July 2026, aiming to expand Stereotaxis's robotic technology portfolio.

Stereotaxis, Inc. has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions. This acquisition aims to strengthen Stereotaxis' position in endovascular procedures by combining complementary robotic technologies. The deal is expected to contribute approximately $2 million in annual revenue during the first year post-acquisition and become breakeven by the third year.